-

Early Warning News Release Regarding the Issuance of Securities of ZYUS Life Sciences Corporation

This press release is issued pursuant to the requirements of National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

SASKATOON, Saskatchewan--(BUSINESS WIRE)--On April 14, 2025, Mr. Wayne Brownlee (the "Acquiror"), who serves as a director of ZYUS Life Sciences Corporation (the “Company”) acquired control and direction over an additional 4,875,000 common share purchase warrants (the “Warrants”) in the capital of the Company (TSXV: ZYUS) in connection with the issuance and amendment of certain unsecured loans advanced to the Company (the “Warrant Issuance”). The Warrants have an expiry date of March 28, 2027 and an exercise price of $0.80 per common share.

As a result of the Warrant Issuance, the Acquiror owns and controls an additional 4,875,000 common share purchase warrants, representing approximately 6.56% of the Company’s issued and outstanding common shares as of the closing date of the Acquisition. Prior to the Acquisition, the Acquiror owned and controlled 3,780,943 common shares (“Common Shares”) of the Company and 526,315 Common Share purchase warrants (the “Prior Warrants”), representing approximately 5.08% of the issued and outstanding Common Shares on a non-diluted basis and 5.79% on a partially diluted basis, assuming exercise of such Prior Warrants. The Prior Warrants have an expiry date of August 26, 2026 and exercise price of $1.30 per Common Share. Following the Acquisition, the Acquiror owns or controls 3,780,943 Common Shares and 5,401,315 warrants, representing 5.08% of the issued and outstanding Common Shares on a non-diluted basis and 12.35% on a partially diluted basis, assuming exercise of such Warrants.

The Acquiror acquired the Warrants for investment purposes and has a long‐term view of the investment. The Acquiror intends to review its investment in the Company on a continuing basis and may, from time to time, increase or decrease its beneficial ownership, control, direction or economic exposure over securities of the Company either on the open market or through private acquisitions in the future depending on market conditions, reformulation of plans and/or other relevant factors and subject to applicable securities laws. The Acquiror may, from time to time and at any time, acquire additional securities and/or other equity, debt or other securities or instruments of the Company in the open market or otherwise, and reserves the right to dispose of any or all of the securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the securities, the whole depending on market conditions, the business and prospects of the Company and other relevant factors, including compliance with applicable securities laws.

An early warning report has been filed by the Acquiror under applicable securities laws and will be available on the Company’s SEDAR+ profile at www.sedarplus.ca.

For more information, please contact the Acquiror at 204-407 Downey Road, Saskatoon, SK S7N 4L8; telephone: (306) 242-2357

Contacts

(306) 242-2357

ZYUS Life Sciences Corporation


Release Versions

Contacts

(306) 242-2357

More News From ZYUS Life Sciences Corporation

ZYUS Life Sciences Corporation Announces Issuance of Bonus Warrants Pursuant to Loan Agreements

SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, announces that it has received conditional acceptance from the TSX Venture Exchange (the “Exchange”) to issue certain common share purchase warrants to independent directors of the Company (“Lenders”) in connection with the issu...

ZYUS Life Sciences Corporation Announces Assumption and Amendment of Promissory Note

SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, announces that a Promissory Note Agreement having a maturity date of August 27, 2025 (the “Promissory Note”) previously entered between its wholly-owned subsidiary ZYUS Life Sciences Inc. (“ZYUS Inc.”) and an independent directo...

ZYUS Life Sciences Corporation Announces Close of Unsecured Loan and Amendment to Prior Unsecured Loans

SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that an independent director of the Company (the “Lender”) has advanced a CAD$1,500,000 unsecured loan (the “Loan”) to the Company which closed on March 7, 2025, subject to the Company filing notice of the...
Back to Newsroom